Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.
Saved in:
| Title: | Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. |
|---|---|
| Authors: | Rousset M; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France. Electronic address: marine.rousset@u-bordeaux.fr., Dutriaux C; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Bosco-Lévy P; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France., Prey S; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Pham-Ledard A; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, F-33000, France., Dousset L; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Gérard E; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Bouchet S; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France., Canal-Raffin M; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team Cancer-environnement-EPICENE, UMR 1219, F-33000 Bordeaux, France., Titier K; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Molimard M; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France. Electronic address: mathieu.molimard@u-bordeaux.fr. |
| Source: | Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2017 Sep; Vol. 472, pp. 26-29. Date of Electronic Publication: 2017 Jul 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 1302422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3492 (Electronic) Linking ISSN: 00098981 NLM ISO Abbreviation: Clin Chim Acta Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 28709799 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rousset+M%22">Rousset M</searchLink>; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France. Electronic address: marine.rousset@u-bordeaux.fr.<br /><searchLink fieldCode="AU" term="%22Dutriaux+C%22">Dutriaux C</searchLink>; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Bosco-Lévy+P%22">Bosco-Lévy P</searchLink>; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Prey+S%22">Prey S</searchLink>; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Pham-Ledard+A%22">Pham-Ledard A</searchLink>; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; EA2406 Histology and Molecular Pathology of Tumors, University of Bordeaux, F-33000, France.<br /><searchLink fieldCode="AU" term="%22Dousset+L%22">Dousset L</searchLink>; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Gérard+E%22">Gérard E</searchLink>; Département de Dermatologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Bouchet+S%22">Bouchet S</searchLink>; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Canal-Raffin+M%22">Canal-Raffin M</searchLink>; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team Cancer-environnement-EPICENE, UMR 1219, F-33000 Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Titier+K%22">Titier K</searchLink>; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.<br /><searchLink fieldCode="AU" term="%22Molimard+M%22">Molimard M</searchLink>; Département de Pharmacologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France; Univ. Bordeaux INSERM, Bordeaux Population Health Research Center, team PHARMACOEPIDEMIOLOGY, UMR 1219, F-33000 Bordeaux, France. Electronic address: mathieu.molimard@u-bordeaux.fr. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%221302422%22">Clinica chimica acta; international journal of clinical chemistry</searchLink> [Clin Chim Acta] 2017 Sep; Vol. 472, pp. 26-29. <i>Date of Electronic Publication: </i>2017 Jul 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>1302422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1873-3492 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200098981%22">00098981 </searchLink><i>NLM ISO Abbreviation: </i>Clin Chim Acta <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28709799 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.cca.2017.07.012 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 26 Titles: – TitleFull: Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rousset M – PersonEntity: Name: NameFull: Dutriaux C – PersonEntity: Name: NameFull: Bosco-Lévy P – PersonEntity: Name: NameFull: Prey S – PersonEntity: Name: NameFull: Pham-Ledard A – PersonEntity: Name: NameFull: Dousset L – PersonEntity: Name: NameFull: Gérard E – PersonEntity: Name: NameFull: Bouchet S – PersonEntity: Name: NameFull: Canal-Raffin M – PersonEntity: Name: NameFull: Titier K – PersonEntity: Name: NameFull: Molimard M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2017 Sep Type: published Y: 2017 Identifiers: – Type: issn-electronic Value: 1873-3492 Numbering: – Type: volume Value: 472 Titles: – TitleFull: Clinica chimica acta; international journal of clinical chemistry Type: main |
| ResultId | 1 |